[1] SHEN YC, HUANG S G, KANG J, et al. Management of airway mucus hypersecretion in chronic airway inflammatory disease:Chinese expert consensus (English edition)[J]. Int J Chron Obstruct Pulmon Dis, 2018,13:399-407. [2] ERDIL N, EROGLU T, AKCA B, et al. The effects of N-acetylcysteine on pulmonary functions in patients undergoing on-pump coronary artery surgery:a double blind placebo controlled study[J]. Eur Rev Med Pharmacol Sci, 2016,20(1):180-187. [3] JOHNSON K, MCEVOY C E, NAQVI S, et al. High-dose oral N-acetylcysteine fails to improve respiratory health status in patients with chronic obstructive pulmonary disease and chronic bronchitis:a randomized, placebo-controlled trial[J]. Int J Chron Obstruct Pulmon Dis, 2016,11:799-807. [4] CAZZOLA M, CALZETTA L, PAGE C, et al. Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations:a meta-analysis[J]. Eur Respir Rev, 2015,24(137):451-461. [5] 王鹏. N-乙酰半胱氨酸对高风险COPD患者肺功能及生活质量的影响[J]. 首都食品与医药, 2018,25(12):40. [6] ZHENG J P, KANG J, HUANG S G, et al. Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study):a randomised placebo-controlled study[J]. Lancet, 2008,371(9629):2013-2018. [7] ZHANG J Q, ZHANG J Q, LIU H, et al. Effect of N-acetylcysteine in COPD patients with different microsomal epoxide hydrolase genotypes[J]. Int J Chron Obstruct Pulmon Dis, 2015,10:917-923. [8] 王飞. N-乙酰半胱氨酸对AECOPD机械通气患者炎症应激指标的影响[J]. 浙江中西医结合杂志, 2018,28(11):930-933. [9] 慢性阻塞性肺疾病急性加重(AECOPD)诊治专家组. 慢性阻塞性肺疾病急性加重(AECOPD)诊治中国专家共识(2017年更新版)[J]. 国际呼吸杂志, 2017,37(14):1041-1057. [10] 中华医学会呼吸病学分会慢性阻塞性肺疾病学组. 慢性阻塞性肺疾病诊治指南(2013年修订版)[J]. 中华结核和呼吸杂志, 2013,36(4):255-264. [11] SINGH D, AGUSTI A, ANZUETO A, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease:The GOLD Science Committee Report 2019[J]. Eur Respir J, 2019,53(5):1900164. [12] PISTELLI R, LANGE P, MILLER D L. Determinants of prognosis of COPD in the elderly:mucus hypersecretion, infections, cardiovascular comorbidity[J]. Eur Respir J Suppl, 2003,40:10s-14s. [13] SETHI S, MURPHY T F. Infection in the pathogenesis and course of chronic obstructive pulmonary disease[J]. N Engl J Med, 2008,359(22):2355-2365. [14] BLASI F, PAGE C, ROSSOLINI GM, et al. The effect of N-acetylcysteine on biofilms:Implications for the treatment of respiratory tract infections[J]. Respir Med, 2016,117:190-197. [15] KIRKHAM P A, BARNES P J. Oxidative stress in COPD[J]. Chest, 2013,144(1):266-273. [16] 庄英鸿, 尚东, 巫瑞,等. 噻托溴铵联合布地奈德福莫特罗吸入剂治疗稳定期慢性阻塞性肺疾病的临床疗效研究[J]. 药物评价研究, 2017,40(11):1626-1630. [17] ZHENG JP, WEN FQ, BAI CX, et al. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON):a randomised, double-blind placebo-controlled trial[J]. Lancet Respir Med, 2014,2(3):187-194. [18] CAZZOLA M, CALZETTA L, FACCIOLO F, et al. Pharmacological investigation on the anti-oxidant and anti-inflammatory activity of N-acetylcysteine in an ex vivo model of COPD exacerbation[J]. Respir Res, 2017,18(1):26. [19] SALVE VT, ATRAM JS. N-acetylcysteine combined with home based physical activity:effect on health related quality of life in stable COPD patients-A randomised controlled trial[J]. J Clin Diagn Res, 2016,10(12):OC16-OC19. [20] SANTUS P, CORSICO A, SOLIDORO P, et al. Oxidative stress and respiratory system:pharmacological and clinical reappraisal of N-acetylcysteine[J]. COPD, 2014,11(6):705-717. [21] 任柏沉, 孙建, 张维,等. 大剂量N-乙酰半胱氨酸治疗158例急性加重期慢性阻塞性肺疾病临床研究[J]. 实用医院临床杂志, 2016,13(5):153-156. |